Peran Radiasi dalam Tatalaksana Retinoblastoma

Aurika Sinambela; H.M Djakaria

doi:10.32532/jori.v8i2.64

Peran Radiasi dalam Tatalaksana Retinoblastoma

Aurika Sinambela, H.M Djakaria

Sari

Retinoblastoma merupakan keganasan orbita tersering pada anak. Leukokoria merupakan tanda utama pada 80% pasien, diikuti strabismus, penurunan visus, hingga perdarahan vitreus pada penyakit stadium lanjut. Retinoblstoma dapat bersifat unilateral maupun bilateral, herediter maupun non-herediter, di mana terjadi mutasi pada kedua alel gen RB1 pada lengan panjang kromosom 13 (13q14). Tujuan utama terapi retinoblastoma adalah penyelamatan hidup pasien dan tujuan sekundernya adalah penyelamatan bola mata dan fungsi penglihatan. Agar tujuan ini tercapai, diagnosis dini dan tatalaksana multimodalitas yang terdiri atas kemoterapi, terapi fokal, operasi, dan radiasi oleh tim multidisiplin diperlukan. Laju sintasan retinoblastoma pada negara berkembang mencapai >95% namun pada negara sedang berkembang, mortalitas retinoblastoma masih tinggi, mencapai 40-70% karena keterlambatan diagnosis dan terapi.

Kata Kunci

Radiasi; Radioterapi; Onkologi; Retinoblastoma

Teks Lengkap:

PDF

Referensi

American Cancer Society. Cancer Facts and Figures 2017. Genes Dev. 2017;21(20):2525–38.

Delhiwala KS, Vadakkal IP, Mulay K, Khetan V, Wick MR. Retinoblastoma: An update. Semin Diagn Pathol. 2016;33(3):133–40.

Ghassemi F, Khodabande A. Risk definition and management strategies in retinoblastoma: Current perspectives. Clin Ophthalmol. 2015;9:985–94.

Sanfilippo NJ, Formenti SC. Eye and Orbit. In: Halperin E, Wazer D, Perez C, Brady L, editors. Perez and Brady’s Principles and Practice of Radiation Oncology. 6th ed. Philadelphia: Lippincot Williams & Wilkins; 2013. p. 696–711.

Kim J-Y, Park Y. Treatment of Retinoblastoma: The Role of External Beam Radiotherapy. Yonsei Med J [Internet]. 2015;56(6):1478–91. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4630033&tool=pmcentrez&rendertype=abstract

Mallipatna AC, Gallie BL, Barrios PC, Rouic LL-L, Chantada GL, Doz F, et al. Retinoblastoma. In: Amin BM, Edge SB, Greene FL, Schilsky RL, Gaspar LF, Washington MK, et al., editors. AJCC Cancer Staging Manual. 8th ed. Chicago: Springer; 2017. p. 819–29.

Yanık Ö, Gündüz K, Yavuz K, Taçyıldız N, Ünal E. Chemotherapy in retinoblastoma: Current approaches. Turk Oftalmoloiji Derg. 2015;45(6):259–67.

Azary S, Ganguly A, Bunin GR, Lombardi C, Park AS, Ritz B, et al. Sporadic retinoblastoma and parental smoking and alcohol consumption before and after conception: A report from the children’s oncology group. PLoS One. 2016;11(3):1–16.

Olch AJ. Retinoblastoma. In: Pediatric Radiotherapy Planning and Treatment. Florida: CRC Press Taylor & Francis Group; 2013. p. 289–322.

Fontanesi J, Taub J, Kirkpatrick JP, Halperin EC. Retinoblastoma. In: Halperin EC, Constine LS, Tarbell NJ, Kun LE, editors. Pediatric Radiation Oncology. 5th ed. Philadelphia: Lippincot Williams & Wilkins; 2011. p. 85–107.

For U. National retinoblastoma strategy Canadian guidelines for care. Can J Ophthalmol / J Can d’Ophtalmologie [Internet]. 2009;44:S9–47. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0008418209801798

Komite Nasional Penanggulangan Kanker (KPKN). Panduan Nasional Penanganan Kanker: Retinoblastoma. 1st ed. Jakarta: Kementerian Kesehatan Republik Indonesia; 2015. 8 p.

Lee AW, Lydiatt WM, Colevas AD, Glastonbury CM, Le QTX, O’Sullivan B, et al. AJCC Cancer Staging Manual. 8th ed. Amin MB, editor. Chicago: Springer; 2017. 103-112 p.

Chawla B, Singh R. Recent advances and challenges in the management of retinoblastoma. Indian J Ophthalmol. 2017;65(2):133–9.

Orman A, Koru-Sengul T, Miao F, Markoe A, Panoff JE. The modern role of radiation therapy in treating advanced-stage retinoblastoma: Long-term outcomes and racial differences. Int J Radiat Oncol Biol Phys [Internet]. 2014;90(5):1037–43. Available from: http://dx.doi.org/10.1016/j.ijrobp.2014.08.336

Mansur DB. Retinoblastoma. In: Lu JJ, Brady LW, editors. Decision Making in Radiation Oncology Volume 2. Philadelphia: Springer-Verlag Berlin Heidelberg; 2011. p. 1037–52.

Krasin MJ, Crawford BT, Zhu Y, Evans ES, Sontag MR, Kun LE, et al. Intensity-modulated radiation therapy for children with intraocular retinoblastoma: Potential sparing of the bony orbit. Clin Oncol. 2004;16(3):215–22.

Temming P, Arendt M, Viehmann A, Eisele L, Le Guin CHD, Schündeln MM, et al. Incidence of second cancers after radiotherapy and systemic chemotherapy in heritable retinoblastoma survivors: A report from the German reference center. Pediatr Blood Cancer. 2017;64(1):71–80.

Wong JR, Morton LM, Tucker MA, Abramson DH, Seddon JM, Sampson JN, et al. Risk of subsequent malignant neoplasms in long-term Hereditary retinoblastoma survivors after chemotherapy and radiotherapy. J Clin Oncol. 2014;32(29):3284–90.

Jong MC De, Kors WA, Graaf P De, Castelijns JA, Moll AC. Trilateral retinoblastoma: a systematic review and meta-analysis. Lancet Oncol. 2014;122–39.

Kleinerman RA, Tucker MA, Tarone RE, Abramson DH, Seddon JM, Stovall M, et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: An extended follow-up. J Clin Oncol. 2005;23(10):2272–9.

Abramson DH, Ellsworth RM, Kitchin FD, Tung G. Second Nonocular Tumors in Retinoblastoma Survivors: Are They Radiation-induced? Ophthalmology [Internet]. 1984;91(11):1351–5. Available from: http://dx.doi.org/10.1016/S0161-6420(84)34127-6

Wong FL, Boice JD, Abramson DH, Tarone RE, Kleinerman R a, Stovall M, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. Jama [Internet]. 1997;278(15):1262–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9333268

Marees T, Moll AC, Imhof SM, De Boer MR, Ringens PJ, Van Leeuwen FE. Risk of second malignancies in survivors of retinoblastoma: More than 40 years of follow-up. J Natl Cancer Inst. 2008;100(24):1771–9.

DOI: https://doi.org/10.32532/jori.v8i2.64 <